scholarly journals Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure

Critical Care ◽  
2014 ◽  
Vol 18 (1) ◽  
pp. R20 ◽  
Author(s):  
Philipp Wohlfarth ◽  
Roman Ullrich ◽  
Thomas Staudinger ◽  
Andja Bojic ◽  
Oliver Robak ◽  
...  
Keyword(s):  
Respiratory Failure ◽  
Extracorporeal Membrane Oxygenation ◽  
Acute Respiratory Failure ◽  
Hematologic Malignancies ◽  
Adult Patients ◽  
Membrane Oxygenation

Extracorporeal membrane oxygenation in adult patients with severe acute respiratory failure

2012 ◽  
Vol 57 (3) ◽  
pp. 303-311 ◽  
Author(s):  
C. LINDSKOV ◽  
R. H. JENSEN ◽  
P. SPROGOE ◽  
K. E. KLAABORG ◽  
H. KIRKEGAARD ◽  
...  
Keyword(s):  
Respiratory Failure ◽  
Extracorporeal Membrane Oxygenation ◽  
Acute Respiratory Failure ◽  
Adult Patients ◽  
Membrane Oxygenation

Evaluation of Bivalirudin as the Primary Anticoagulant in Patients Receiving Extracorporeal Membrane Oxygenation for SARS-CoV-2–Associated Acute Respiratory Failure

2021 ◽  
pp. 106002802110361
Author(s):  
Brittany D. Bissell ◽  
Taylor Gabbard ◽  
Erica A. Sheridan ◽  
Maher A. Baz ◽  
George A. Davis ◽  
...  
Keyword(s):  
Respiratory Failure ◽  
Extracorporeal Membrane Oxygenation ◽  
Acute Respiratory Failure ◽  
Retrospective Chart Review ◽  
Venous Thromboembolic Event ◽  
Membrane Oxygenation ◽  
Published Report ◽  
Starting Dose ◽  
Venous Thromboembolic ◽  
Polymerase Chain

Background Extracorporeal membrane oxygenation (ECMO) is a potential option for the management of severe acute respiratory failure secondary to COVID-19. Conflicting the use of this therapy is the known coagulopathy within COVID-19, leading to an incidence of venous thrombotic events of 25% to 49%. To date, limited guidance is available on optimal anticoagulation strategies in this population. Objective The purpose of this study was to evaluate the utilization of a pharmacist-driven bivalirudin dosing protocol for anticoagulation in the setting of ECMO for COVID-19–associated respiratory failure. Methods This was a single-center retrospective chart review over a 9-month period of patients receiving bivalirudin while on ECMO. All patients with acute respiratory failure requiring ECMO with a positive SARS-CoV-2 polymerase chain reaction were included. Bivalirudin was dosed via aPTT monitoring after a starting dose of 0.2 or 0.3 mg/kg/h. Results There were 33 patients included in this study, all receiving mechanical ventilation. The most common starting dose of bivalirudin was 0.2 mg/kg/h, with an average time to therapeutic range of 20 hours. Compared to previous reports, rates of bleeding were low at 15.1%, and 6.1% of patients developed a new venous thromboembolic event while on ECMO. ECMO survival was 51.5%, with an ICU mortality rate of 48.5%. Conclusion and Relevance In the first published report of its use within this population, bivalirudin was found to be a viable choice for anticoagulation in those patients on ECMO for severe respiratory failure secondary to COVID-19.

Current Status of Prolonged Extracorporeal Membrane Oxygenation for Acute Respiratory Failure

CHEST Journal ◽  
1973 ◽  
Vol 63 (5) ◽  
pp. 773-782 ◽  
Author(s):  
Edward A. Lefrak ◽  
Paul M. Stevens ◽  
George P. Noon ◽  
Michael E. DeBakey
Keyword(s):  
Respiratory Failure ◽  
Extracorporeal Membrane Oxygenation ◽  
Acute Respiratory Failure ◽  
Current Status ◽  
Membrane Oxygenation
Sign in / Sign up

Export Citation Format

Share Document